Biomarkers for Early Detection of Malignant Mesothelioma: Diagnostic and Therapeutic Application
Abstract
:1. Introduction
2. Biomarkers
2.1. Biomarkers of Exposure
DNA Adducts
2.2. Biomarkers of Early Effect
2.2.1. DNA Repair Ability
2.2.2. Cytogenetic Assay
2.3. Biomarker for Diagnosis
2.3.1. Conventional Biomarkers
2.3.2. Osteopontin
Studies | N° | Sample | Biomarker cut-off (ng/mL) | Sensitivity % | Specificity % | AUC |
---|---|---|---|---|---|---|
OPN | ||||||
Pass et al. [45] | 193 | serum | 43.3 | 77.6 | 85.5 | 0.89 (0.83–0.93) |
Paleari et al. [55] | 94 | plasma | 60.8 | 40.0 | 100.0 | 0.60 (0.47–0.72) |
Grigoriu et al. [52] | 208 | serum | 68.0 | 95.0 | 50.0 | 0.74 (0.68–0.79) |
Creany et al. [74] | 107 | serum | 18.0 | 47.0 | 95.0 | 0.76 (0.67–0.85) |
SMRPs | ||||||
Grigoriu et al. [52] | 208 | serum | 1.7 | 40.0 | 100.0 | 0.74 (0.68–0.80) |
Scherpereel et al. [61] | 137 | serum | 1.1 | 71.7 | 69.8 | 0.79 (0.73–0.85) |
Rodriguez et al. [65] | 362 | serum | 1.1 | 24.0 | 97.2 | 0.75 (0.68–0.83) |
Amati et al. [24] | 170 | plasma | 1.0 | 90.0 | 78.0 | 0.93 (0.88–0.97) |
Iwahori et al. [66] | 121 | serum | 93.5 | 59.3 | 86.2 | 0.71 |
Beyer et al. [67] | 497 | serum | 1.0 | 68.2 | 77.0 | – |
Cristaudo et al. [68] | 369 | serum | 1.0 | 68.2 | 80.5 | 0.77 (0.71–0.83) |
Creany et al. [74] | 107 | serum | 1.6 | 73.0 | 95.0 | 0.92 (0.87–0.97) |
Hollevoet et al. [75] | 507 | serum | 2.0 | – | 64.0 | 0.87 |
Creaney et al. [77] | 233 | serum | 1.4 | – | 67.0 | 0.77 |
MPF | ||||||
Iwahori et al. [65] | 121 | serum | 19.1 | 74.1 | 90.4 | 0.88 |
Creany et al. [74] | 107 | serum | 1.0 | 34.0 | 95.0 | 0.61 (0.51–0.72) |
Hollevoet et al. [75] | 507 | serum | 12.4 | – | 68.0 | 0.85 |
2.3.3. Soluble Mesothelin-Related Peptides
2.3.4. Biomarker Combination
Marker | Ctrl vs. Exp (AUC) | Exp vs. MM (AUC) | Ctrl vs. MM (AUC) |
---|---|---|---|
8OHdG (AU) | 0.775 ± 0.037 | 0.566 ± 0.110 | 0.788 ± 0.090 |
VEGF (ng/mL) | 0.714 ± 0.062 | 0.705 ± 0.086 | 0.803 ± 0.074 |
SMRPs (nM) | 0.459 ± 0.042 | 0.927 ± 0.022 | 0.920 ± 0.030 |
8OHdG-VEGF-SMRPs | 0.925 ± 0.035 | - | - |
2.3.5. Molecular Biomarkers
2.4. Prognostic Biomarkers
2.5. Target Biomarkers
2.6. Predictive Biomarkers
3. Conclusions
References
- Price, B.; Ware, A. Mesothelioma trends in the United States: an update based on Surveillance, Epidemiology, and End Results Program data for 1973 through 2003. Am. J. Epidemiol. 2004, 159, 107–112. [Google Scholar] [CrossRef]
- Peto, J.; Decarli, A.; La Vecchia, C.; Levi, F.; Negri, E. The European mesothelioma epidemic. Br. J. Cancer 1999, 79, 666–672. [Google Scholar] [CrossRef]
- Bourdès, V.; Boffetta, P.; Pisani, P. Environmental exposure to asbestos and risk of pleural mesothelioma: review and meta-analysis. Eur. J. Epidemiol. 2000, 16, 411–417. [Google Scholar] [CrossRef]
- Hansen, J.; de Klerk, N.H.; Musk, A.W.; Hobbs, M.S.T. Environmental exposure to crocidolite and mesothelioma. Exposure-response relationships. Am. J. Respir. Crit. Care Med. 1998, 157, 69–75. [Google Scholar] [CrossRef]
- Musti, M.; Kettunen, E.; Dragonieri, S.; Lindholm, P.; Cavone, D.; Serio, G.; Knuutila, S. Cytogenetic and molecular genetic changes in malignant mesothelioma. Cancer Genet. Cytogenet. 2006, 170, 9–15. [Google Scholar]
- Shin, H.J.; Shin, D.M.; Tarco, E.; Sneige, N. Detection of numerical aberrations of chromosomes 7 and 9 in cytologic specimens of pleural malignant mesothelioma. Cancer 2003, 99, 233–239. [Google Scholar] [CrossRef]
- Scherpereel, A.; Astoul, P.; Baas, P.; Berghmans, T.; Clayson, H.; de Vuyst, P.; Dienemann, H.; Galateau–Salle, F.; Hennequin, C.; Hillerdal, G.; Le Péchoux, C.; Mutti, L.; Pairon, J.C.; Stahel, R.; van Houtte, P.; van Meerbeeck, J.; Waller, D.; Weder, W. Guidelines of the European Respiratory Society and the European Society of Thoracic Surgeons for the management of malignant pleural mesothelioma. Eur. Respir J. 2010, 35, 479–495. [Google Scholar] [CrossRef]
- Cresoli, G.L.; Gridelli, C.; Santoro, A. Multidisciplinary treatment of malignant pleural mesothelioma. Oncologist 2007, 12, 850–863. [Google Scholar] [CrossRef]
- Scagliotti, G.V.; Selvaggi, G. Advances in diagnosis and treatment of malignant mesothelioma. Oncol. Rev. 2007, 1, 91–102. [Google Scholar] [CrossRef]
- Biomarkers Definitions Working Group. Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin. Pharmacol. Ther. 2001, 69, 29–95.
- Jaurand, M.C. Mechanisms of fiber-induced genotoxicity. Environ. Health Perspect. 1997, 5, 1073–1084. [Google Scholar]
- Unfried, K.; Schurkes, C.; Abel, J. Distinct spectrum of mutations induced by crocidolite asbestos: clue for 8-hydroxydeoxyguanosine-dependent mutagenesis in vivo. Cancer Res. 2002, 62, 99–104. [Google Scholar]
- Moriya, M. Single-stranded shuttle phagemid for mutagenesis studies in mammalian cells: 8-oxoguanine in DNA induced targeted G.C → T.A transversions in simian kidney cells. Proc. Natl. Acad. Sci. USA 1993, 90, 1122–1126. [Google Scholar] [CrossRef]
- Halliwell, B. Oxidative stress and cancer: have we moved forward? Biochem. J. 2007, 401, 1–11. [Google Scholar]
- Halliwell, B. Can oxidative DNA damage be used as a biomarker of cancer risk in human? Problems, resolutions and preliminary results from nutritional supplementation studies. Free Radical Res. 1998, 29, 469–486. [Google Scholar] [CrossRef]
- Takahashi, K.; Pan, G.; Kasai, H.; Hanaoka, T.; Feng, Y.; Liu, N.; Zhang, S.; Xu, Z.; Tsuda, T.; Yamato, H.; Higashi, T.; Okubo, T. Relationship between Asbestos Exposures and 8-Hydroxydeoxyguanosine Levels in Leukocytic DNA of Workers at a Chinese Asbestos-material Plant. Int. J. Occup. Environ. Health 1997, 3, 111–119. [Google Scholar]
- Marczynski, B.; Kraus, T.; Rozynek, P.; Raithel, H.J.; Baur, X. Association between 8-hydroxy-2′-deoxyguanosine levels in DNA of workers highly exposed to asbestos and their clinical data, occupational and non-occupational confounding factors, and cancer. Mutat. Res. 2000, 468, 203–212. [Google Scholar] [CrossRef]
- Valavanidis, A.; Vlachogianni, T.; Fiotakis, C. 8-hydroxy-2'-deoxyguanosine (8-OHdG): A Critical Biomarker of Oxidative Stress and Carcinogenesis. J. Environ. Sci. Health 2009, 27, 20–139. [Google Scholar]
- Takeuchi, T.; Nakajima, M.; Morimoto, K. Relationship between the intracellular reactive oxygen species and the induction of oxidative DNA damage in human neutrophil-like cells. Carcinogenesis 1996, 17, 1543–1548. [Google Scholar] [CrossRef]
- Sabatini, L.; Barbieri, A.; Tosi, M.; Roda, A.; Violante, F.S. A method for routine quntification of urinary 8-hydroxy-2’-deoxyguanosine based on solid-phase extraction and micro-high-performance liquid chromatography/electrospry ionization tandem mass spectrometry. Rapid Commun. Mass Spectrom. 2005, 19, 147–152. [Google Scholar]
- Collins, A.R.; Dusinská, M.; Horváthová, E.; Munro, E.; Savio, M.; Stĕtina, R. Inter-individual differences in repair of DNA base oxidation, measured in vitro with the comet assay. Mutagenesis 2001, 16, 297–301. [Google Scholar] [CrossRef]
- Tomasetti, M.; Alleva, R.; Borghi, B.; Collins, A.R. In vivo supplementation with coenzyme Q10 enhances the recovery of human lymphocytes from oxidative DNA damage. FASEB J. 2001, 15, 1425–1427. [Google Scholar]
- De Iuliis, G.N.; Thomson, L.K.; Mitchell, L.A.; Finnie, J.M.; Koppers, A.J.; Hedges, A.; Nixon, B.; Aitken, R.J. DNA damage in human spermatozoa is highly correlated with the efficiency of chromatin remodeling and the formation of 8-hydroxy-2'-deoxyguanosine, a marker of oxidative stress. Biol. Reprod. 2009, 81, 517–524. [Google Scholar] [CrossRef]
- Amati, M.; Tomasetti, M.; Scartozzi, M.; Mariotti, L.; Alleva, R.; Pignotti, E.; Borghi, B.; Valentino, M.; Governa, M.; Neuzil, J.; Santarelli, L. Profiling tumor-associated markers for early detection of malignant mesothelioma: an epidemiologic study. Cancer Epidemiol. Biomarkers Prev. 2008, 17, 163–170. [Google Scholar] [CrossRef]
- Amati, M.; Tomasetti, M.; Mariotti, L.; Tarquini, L.M.; Valentino, M.; Santarelli, L. Assessment of biomarkers in asbestos-exposed workers as indicators of cancer risk. Mutat. Res. 2008, 655, 52–58. [Google Scholar] [CrossRef]
- Roushdy-Hammady, I.; Siegel, J.; Emri, S.; Testa, J.R.; Carbone, M. Genetic-susceptibility factor and malignant mesothelioma in the Cappadocian region of Turkey. Lancet 2001, 357, 444–445. [Google Scholar]
- Dusinská, M.; Collins, A.; Kazimírová, A.; Barancoková, M.; Harrington, V.; Volkovová, K.; Staruchová, M.; Horská, A.; Wsólová, L.; Kocan, A.; Petrík, J.; Machata, M.; Ratcliffe, B.; Kyrtopoulos, S. Genotoxic effects of asbestos in humans. Mutat. Res. 2004, 553, 91–102. [Google Scholar] [CrossRef]
- Dusinská, M.; Barancoková, M.; Kazimírová, A.; Harrington, V.; Volkovová, K.; Staruchová, M.; Horská, A.; Wsólová, L.; Collins, A. Does occupational exposure to mineral fibres cause DNA or chromosome damage? Mutat. Res. 2004, 553, 103–110. [Google Scholar]
- Leprat, F.; Alapetite, C.; Rosselli, F.; Ridet, A.; Schlumberger, M.; Sarasin, A.; Suarez, H.G.; Moustacchi, E. Impaired DNA repair as assessed by the "comet" assay in patients with thyroid tumors after a history of radiation therapy: a preliminary study. Int. J. Radiat. Oncol. Biol. Phys. 1998, 40, 1019–1026. [Google Scholar] [CrossRef]
- Jałoszyński, P.; Kujawski, M.; Czub-Swierczek, M.; Markowska, J.; Szyfter, K. Bleomycin-induced DNA damage and its removal in lymphocytes of breast cancer patients studied by comet assay. Mutat. Res. 1997, 385, 223–233. [Google Scholar] [CrossRef]
- Schmezer, P.; Rajaee-Behbahani, N.; Risch, A.; Thiel, S.; Rittgen, W.; Drings, P.; Dienemann, H.; Kayser, K.W.; Schulz, V.; Bartsch, H. Rapid screening assay for mutagen sensitivity and DNA repair capacity in human peripheral blood lymphocytes. Mutagenesis 2001, 16, 25–30. [Google Scholar] [CrossRef]
- Bonassi, S.; Hagmar, L.; Strömberg, U.; Montagud, A.H.; Tinnerberg, H.; Forni, A.; Heikkilä, P.; Wanders, S.; Wilhardt, P.; Hansteen, I.L.; Knudsen, L.E.; Norppa, H. Chromosomal aberrations in lymphocytes predict human cancer independently of exposure to carcinogens. European Study Group on Cytogenetic Biomarkers and Health. Cancer Res. 2000, 60, 1619–1625. [Google Scholar]
- Rossner, P.; Boffetta, P.; Ceppi, M.; Bonassi, S.; Smerhovsky, Z.; Landa, K.; Juzova, D.; Srám, R.J. Chromosomal aberrations in lymphocytes of healthy subjects and risk of cancer. Environ. Health Perspect. 2005, 113, 517–520. [Google Scholar]
- Trenz, K.; Rothfuss, A.; Schütz, P.; Speit, G. Mutagen sensitivity of peripheral blood from women carrying a BRCA1 or BRCA2 mutation. Mutat. Res. 2002, 500, 89–96. [Google Scholar] [CrossRef]
- Bolognesi, C.; Filiberti, R.; Neri, M.; Perrone, E.; Landini, E.; Canessa, P.A.; Simonassi, C.; Cerrano, P.G.; Mutti, L.; Puntoni, R. High frequency of micronuclei in peripheral blood lymphocytes as index of susceptibility to pleural malignant mesothelioma. Cancer Res. 2002, 62, 5418–5419. [Google Scholar]
- Carbone, M.; Kratzke, R.A.; Testa, J.R. The pathogenesis of mesothelioma. Semin. Oncol. 2002, 29, 2–17. [Google Scholar] [CrossRef]
- Alatas, F.; Alatas, O.; Metintas, M.; Golak, O.; Harmanci, E.; Demir, S. Diagnostic value of CEA, CA 15-3, CA 19-9, CYFRA 21-1, NSE and TSA assay in pleural effutions. Lung Cancer 2001, 31, 9–16. [Google Scholar]
- Paganuzzi, M.; Onetto, M.; Marroni, P.; Filiberti, R.; Tassara, E.; Parodi, S.; Felletti, R. Diagnostic value of CYFRA 21-1 tumor marker and CEA in pleural effusion due to mesothelioma. Chest 2001, 119, 1138–1142. [Google Scholar]
- Grigoriu, B.D.; Grigoriu, C.; Chahine, B.; Gey, T.; Scherpereel, A. Clinical utility of diagnostic markers for malignant pleural mesothelioma. Monaldi Arch. Chest Dis. 2009, 71, 31–38. [Google Scholar]
- van den Heuvel, M.M.; Korse, C.M.; Bonfrer, J.M.; Baas, P. Non-invasive diagnosis of pleural malignancies: the role of tumour markers. Lung Cancer 2008, 59, 350–354. [Google Scholar] [CrossRef]
- Bonfrer, J.M.; Schouwink, J.H.; Korse, C.M.; Baas, P. Cyfra 21-1 and TPA as markers in malignant mesothelioma. Anticancer Res. 1997, 17, 2971–2973. [Google Scholar]
- Salama, G.; Miédougé, M.; Rouzaud, P.; Mauduyt, M.A.; Pujazon, M.C.; Vincent, C.; Carles, P.; Serre, G. Evaluation of pleural CYFRA 21-1 and carcinoembryonic antigen in the diagnosis of malignant pleural effusions. Br. J. Cancer 1998, 77, 472–476. [Google Scholar] [CrossRef]
- Romero, S.; Fernández, C.; Arriero, J.M.; Espasa, A.; Candela, A.; Martín, C.; Sánchez-Payá, J. CEA, CA 15-3 and CYFRA 21-1 in serum and pleural fluid of patients with pleural effusions. Eur. Respir. J. 1996, 9, 17–23. [Google Scholar] [CrossRef]
- Porcel, J.M.; Vives, M.; Esquerda, A.; Salud, A.; Pérez, B.; Rodríguez-Panadero, F. Use of a panel of tumor markers (carcinoembryonic antigen, cancer antigen 125, carbohydrate antigen 15-3, and cytokeratin 19 fragments) in pleural fluid for the differential diagnosis of benign and malignant effusions. Chest 2004, 126, 1757–1763. [Google Scholar] [CrossRef]
- Pettersson, T.; Fröseth, B.; Riska, H.; Klockars, M. Concentration of hyaluronic acid in pleural fluid as a diagnostic aid for malignant mesothelioma. Chest 1988, 94, 1037–1039. [Google Scholar] [CrossRef]
- Atagi, S.; Ogawara, M.; Kawahara, M.; Sakatani, M.; Furuse, K.; Ueda, E.; Yamamoto, S. Utility of hyaluronic acid in pleural fluid for differential diagnosis of pleural effusions: likelihood ratios for malignant mesothelioma. Jpn. J. Clin. Oncol. 1997, 27, 293–297. [Google Scholar] [CrossRef]
- Grigoriu, B.; Chahine, B.; Zerimech, F.; Grégoire, M.; Balduyck, M.; Copin, M.C.; Devos, P.; Lassalle, P.; Scherpereel, A. Serum mesothelin has a higher diagnostic utility than hyaluronic acid in malignant mesothelioma. Clin. Biochem. 2009, 42, 1046–1050. [Google Scholar] [CrossRef] [Green Version]
- Pass, H.I.; Lott, D.; Lonardo, F.; Harbut, M.; Liu, Z.; Tang, N.; Carbone, M.; Webb, C.; Wali, A. Asbestos exposure, pleural mesothelioma, and serum osteopontin levels. N. Engl. J. Med. 2005, 353, 1564–1573. [Google Scholar] [CrossRef]
- Cullen, M.R. Serum osteopontin levels--is it time to screen asbestos-exposed workers for pleural mesothelioma? N. Engl. J. Med. 2005, 353, 1617–1618. [Google Scholar] [CrossRef]
- Wai, P.Y.; Kuo, P.C. The role of Osteopontin in tumor metastasis. J. Surg. Res. 2004, 121, 228–241. [Google Scholar] [CrossRef]
- Park, E.K.; Thomas, P.S.; Johnson, A.R.; Yates, D.H. Osteopontin levels in an asbestos-exposed population. Clin. Cancer Res. 2009, 15, 1362–1366. [Google Scholar] [CrossRef]
- Grigoriu, B.D.; Scherpereel, A.; Devos, P.; Chahine, B.; Letourneux, M.; Lebailly, P.; Grégoire, M.; Porte, H.; Copin, M.C.; Lassalle, P. Utility of osteopontin and serum mesothelin in malignant pleural mesothelioma diagnosis and prognosis assessment. Clin. Cancer Res. 2007, 13, 2928–2935. [Google Scholar] [CrossRef]
- Myles, T.; Leung, L.L. Thrombin hydrolysis of human osteopontin is dependent on thrombin anion-binding exosites. J. Biol. Chem. 2008, 283, 17789–17796. [Google Scholar]
- Kazanecki, C.C.; Uzwiak, D.J.; Denhardt, D.T. Control of osteopontin signaling and function by post-translational phosphorylation and protein folding. J. Cell Biochem. 2007, 102, 912–24. [Google Scholar] [CrossRef]
- Paleari, L.; Rotolo, N.; Imperatori, A.; Puzone, R.; Sessa, F.; Franzi, F.; Meacci, E.; Camplese, P.; Cesario, A.; Paganizzi, M. Osteopontin is not a specific marker in malignant pleural mesothelioma. Int. J. Biol. Markers. 2009, 24, 112–117. [Google Scholar]
- Fedarko, N.S.; Jain, A.; Karadag, A.; Van Eman, M.R.; Fisher, L.W. Elevated serum bone sialoprotein and osteopontin in colon, breast, prostate, and lung cancer. Clin. Cancer Res. 2001, 7, 4060–4066. [Google Scholar]
- Ue, T.; Yokozaki, H.; Kitadai, Y.; Yamamoto, S.; Yasui, W.; Ishikawa, T.; Tahara, E. Co-expression of osteopontin and CD44v9 in gastric cancer. Int. J. Cancer. 1998, 79, 127–132. [Google Scholar] [CrossRef]
- Kato, N.; Motoyama, T. Overexpression of osteopontin in clear cell carcinoma of the ovary: close association with HNF-1beta expression. Histopathology 2008, 52, 682–688. [Google Scholar] [CrossRef]
- Zhou, Y.; Dai, D.L.; Martinka, M.; Su, M.; Zhang, Y.; Campos, E.I.; Dorocicz, I.; Tang, L.; Huntsman, D.; Nelson, C.; Ho, V.; Li, G. Osteopontin expression correlates with melanoma invasion. J. Invest. Dermatol. 2005, 124, 1044–1052. [Google Scholar] [CrossRef]
- Robinson, B.W.; Creaney, J.; Lake, R.; Nowak, A.; Musk, A.W.; de Klerk, N.; Winzell, P.; Hellstrom, K.E.; Hellstrom, I. Mesothelin-family proteins and diagnosis of mesothelioma. Lancet 2003, 362, 1612–1616. [Google Scholar] [CrossRef]
- Scherpereel, A.; Grigoriu, B.; Conti, M.; Gey, T.; Grégoire, M.; Copin, M.C.; Devos, P.; Chahine, B.; Porte, H.; Lassalle, P. Soluble mesothelin-related peptides in the diagnosis of malignant pleural mesothelioma. Am. J. Respir. Crit. Care Med. 2006, 173, 1155–1160. [Google Scholar]
- Hartge, P. Designing early detection programs for ovarian cancer. J. Natl. Cancer Inst. 2010, 102, 3–4. [Google Scholar] [CrossRef]
- Johnston, F.M.; Tan, M.C.; Tan, B.R., Jr.; Porembka, M.R.; Brunt, E.M.; Linehan, D.C.; Simon, P.O., Jr.; Plambeck-Suess, S.; Eberlein, T.J.; Hellstrom, K.E.; Hellstrom, I.; Hawkins, W.G.; Goedegebuure, P. Circulating mesothelin protein and cellular antimesothelin immunity in patients with pancreatic cancer. Clin. Cancer Res. 2009, 15, 6511–6518. [Google Scholar] [CrossRef]
- Hassan, R.; Remaley, A.T.; Sampson, M.L.; Zhang, J.; Cox, D.D.; Pingpank, J.; Alexander, R.; Willingham, M.; Pastan, I.; Onda, M. Detection and quantitation of serum mesothelin, a tumor marker for patients with mesothelioma and ovarian cancer. Clin. Cancer Res. 2006, 12, 447–453. [Google Scholar] [CrossRef]
- Rodríguez Portal, J.A.; Rodríguez Becerra, E.; Rodríguez Rodríguez, D.; Alfageme Michavila, I.; Quero Martínez, A.; Diego Roza, C.; León Jiménez, A.; Isidro Montes, I.; Cebollero Rivas, P. Serum levels of soluble mesothelin-related peptides in malignant and nonmalignant asbestos-related pleural disease: relation with past asbestos exposure. Cancer Epidemiol. Biomarkers Prev. 2009, 18, 646–650. [Google Scholar] [CrossRef]
- Iwahori, K.; Osaki, T.; Serada, S.; Fujimoto, M.; Suzuki, H.; Kishi, Y.; Yokoyama, A.; Hamada, H.; Fujii, Y.; Yamaguchi, K.; Hirashima, T.; Matsui, K.; Tachibana, I.; Nakamura, Y.; Kawase, I.; Naka, T. Megakaryocyte potentiating factor as a tumor marker of malignant pleural mesothelioma: evaluation in comparison with mesothelin. Lung Cancer 2008, 62, 45–54. [Google Scholar] [CrossRef]
- Beyer, H.L.; Geschwindt, R.D.; Glover, C.L.; Tran, L.; Hellstrom, I.; Hellstrom, K.E.; Miller, M.C.; Verch, T.; Allard, W.J.; Pass, H.I.; Sardesai, N.Y. MESOMARK: a potential test for malignant pleural mesothelioma. Clin. Chem. 2007, 53, 666–672. [Google Scholar] [CrossRef]
- Cristaudo, A.; Foddis, R.; Vivaldi, A.; Guglielmi, G.; Dipalma, N.; Filiberti, R.; Neri, M.; Ceppi, M.; Paganuzzi, M.; Ivaldi, G.P.; Mencoboni, M.; Canessa, P.A.; Ambrosino, N.; Chella, A.; Mutti, L.; Puntoni, R. Clinical significance of serum mesothelin in patients with mesothelioma and lung cancer. Clin. Cancer Res. 2007, 13, 5076–5081. [Google Scholar] [CrossRef]
- Park, E.K.; Sandrini, A.; Yates, D.H.; Creaney, J.; Robinson, B.W.; Thomas, P.S.; Johnson, A.R. Soluble mesothelin-related protein in an asbestos-exposed population: the dust diseases board cohort study. Am. J. Respir. Crit. Care Med. 2008, 178, 832–837. [Google Scholar] [CrossRef]
- Amati, M.; Tomasetti, M.; Mariotti, L.; Tarquini, L.M.; Valentino, M.; Santarelli, L. Assessment of biomarkers in asbestos-exposed workers as indicators of cancer risk. Mutat. Res. 2008, 655, 52–58. [Google Scholar] [CrossRef]
- Luo, L.; Shi, H.Z.; Liang, Q.L.; Jiang, J.; Qin, S.M.; Deng, J.M. Diagnostic value of soluble mesothelin-related peptides for malignant mesothelioma: A meta-analysis. Respir. Med. 2010, 104, 149–156. [Google Scholar] [CrossRef]
- Shiomi, K.; Miyamoto, H.; Segawa, T.; Hagiwara, Y.; Ota, A.; Maeda, M.; Takahashi, K.; Masuda, K.; Sakao, Y.; Hino, O. Novel ELISA system for detection of N-ERC/mesothelin in the sera of mesothelioma patients. Cancer Sci. 2006, 97, 928–932. [Google Scholar] [CrossRef]
- Onda, M.; Nagata, S.; Ho, M.; Bera, T.K.; Hassan, R.; Alexander, R.H.; Pastan, I. Megakaryocyte potentiation factor cleaved from mesothelin precursor is a useful tumor marker in the serum of patients with mesothelioma. Clin. Cancer Res. 2006, 12, 4225–4231. [Google Scholar] [CrossRef]
- Creaney, J.; Yeoman, D.; Demelker, Y.; Segal, A.; Musk, A.W.; Skates, S.J.; Robinson, B.W. Comparison of osteopontin, megakaryocyte potentiating factor, and mesothelin proteins as markers in the serum of patients with malignant mesothelioma. J. Thorac. Oncol. 2008, 3, 851–857. [Google Scholar] [CrossRef]
- Hollevoet, K.; Nackaerts, K.; Thimpont, J.; Germonpré, P.; Bosquée, L.; De Vuyst, P.; Legrand, C.; Kellen, E.; Kishi, Y.; Delanghe, J.R.; van Meerbeeck, J.P. Diagnostic Performance of Soluble Mesothelin and Megakaryocyte Potentiating Factor in Mesothelioma. Am. J. Respir. Crit. Care Med. 2010, 181, 620–625. [Google Scholar] [CrossRef]
- Shitrit, D.; Zingerman, B.; Shitrit, A.B.; Shlomi, D.; Kramer, M.R. Diagnostic value of CYFRA 21-1, CEA, CA 19-9, CA 15-3, and CA 125 assays in pleural effusions: analysis of 116 cases and review of the literature. Oncologist 2005, 10, 501–507. [Google Scholar] [CrossRef]
- Creaney, J.; van Bruggen, I.; Hof, M.; Segal, A.; Musk, A.W.; de Klerk, N.; Horick, N.; Skates, S.J.; Robinson, B.W. Combined CA125 and mesothelin levels for the diagnosis of malignant mesothelioma. Chest 2007, 132, 1239–1246. [Google Scholar] [CrossRef]
- Jones, P.A.; Baylin, S.B. The fundamental role of epigenetic events in cancer. Nat. Rev. Genet. 2002, 3, 415–428. [Google Scholar]
- Goto, Y.; Shinjo, K.; Kondo, Y.; Shen, L.; Toyota, M.; Suzuki, H.; Gao, W.; An, B.; Fujii, M.; Murakami, H.; Osada, H.; Taniguchi, T.; Usami, N.; Kondo, M.; Hasegawa, Y.; Shimokata, K.; Matsuo, K.; Hida, T.; Fujimoto, N.; Kishimoto, T.; Issa, J.P.; Sekido, Y. Epigenetic profiles distinguish malignant pleural mesothelioma from lung adenocarcinoma. Cancer Res. 2009, 69, 9073–9082. [Google Scholar] [CrossRef]
- Hussain, S.P.; Harris, C.C. Inflammation and cancer: an ancient link with novel potentials. Int. J. Cancer 2007, 121, 2373–2380. [Google Scholar] [CrossRef]
- Tsou, J.A.; Shen, L.Y.; Siegmund, K.D.; Long, T.I.; Laird, P.W.; Seneviratne, C.K.; Koss, M.N.; Pass, H.I.; Hagen, J.A.; Laird-Offringa, I.A. Distinct DNA methylation profiles in malignant mesothelioma, lung adenocarcinoma, and non-tumor lung. Lung Cancer 2005, 47, 193–204. [Google Scholar] [CrossRef]
- Tsou, J.A.; Galler, J.S.; Wali, A.; Ye, W.; Siegmund, K.D.; Groshen, S.; Laird, P.W.; Turla, S.; Koss, M.N.; Pass, H.I.; Laird-Offringa, I.A. DNA methylation profile of 28 potential marker loci in malignant mesothelioma. Lung Cancer 2007, 58, 220–230. [Google Scholar] [CrossRef]
- Yang, H.; Bocchetta, M.; Kroczynska, B.; Elmishad, A.G.; Chen, Y.; Liu, Z.; Bubici, C.; Mossman, B.T.; Pass, H.I.; Testa, J.R.; Franzoso, G.; Carbone, M. TNF-alpha inhibits asbestos-induced cytotoxicity via a NF-kappaB-dependent pathway, a possible mechanism for asbestos-induced oncogenesis. Proc. Natl. Acad. Sci. USA 2006, 103, 10397–10402. [Google Scholar] [CrossRef]
- Shapiro, B.; Chakrabarty, M.; Cohn, E.M.; Leon, S.A. Determination of circulating DNA levels in patients with benign or malignant gastrointestinal disease. Cancer 1983, 51, 2116–2120. [Google Scholar] [CrossRef]
- Fischer, J.R.; Ohnmacht, U.; Rieger, N.; Zemaitis, M.; Stoffregen, C.; Kostrzewa, M.; Buchholz, E.; Manegold, C.; Lahm, H. Promoter methylation of RASSF1A, RARbeta and DAPK predict poor prognosis of patients with malignant mesothelioma. Lung Cancer 2006, 54, 109–116. [Google Scholar] [CrossRef]
- Rauhala, H.E.; Jalava, S.E.; Isotalo, J.; Bracken, H.; Lehmusvaara, S.; Tammela, T.L.; Oja, H.; Visakorpi, T. miR-193b is an epigenetically regulated putative tumor suppressor in prostate cancer. Int. J. Cancer 2010. [Google Scholar] [CrossRef]
- Lodygin, D.; Tarasov, V.; Epanchintsev, A.; Berking, C.; Knyazeva, T.; Körner, H.; Knyazev, P.; Diebold, J.; Hermeking, H. Inactivation of miR-34a by aberrant CpG methylation in multiple types of cancer. Cell Cycle 2008, 7, 2591–2600. [Google Scholar] [CrossRef]
- Wijnhoven, B.P.; Michael, M.Z.; Watson, D.I. MicroRNAs and cancer. Br. J. Surg. 2007, 94, 23–30. [Google Scholar] [CrossRef]
- Croce, C.M. Causes and consequences of microRNA dysregulation in cancer. Nat. Rev. Genet. 2009, 10, 704–714. [Google Scholar] [CrossRef]
- Calin, G.A.; Croce, C.M. MicroRNA signatures in human cancers. Nat. Rev. Cancer 2006, 6, 857–866. [Google Scholar] [CrossRef]
- Lu, J.; Getz, G.; Miska, E.A.; Alvarez-Saavedra, E.; Lamb, J.; Peck, D.; Sweet-Cordero, A.; Ebert, B.L.; Mak, R.H.; Ferrando, A.A.; Downing, J.R.; Jacks, T.; Horvitz, H.R.; Golub, T.R. MicroRNA expression profiles classify human cancers. Nature 2005, 435, 834–838. [Google Scholar] [CrossRef]
- Blenkiron, C.; Miska, E.A. miRNAs in cancer: approaches, aetiology, diagnostics and therapy. Hum. Mol. Genet. 2007, 16, R106–R113. [Google Scholar] [CrossRef]
- Guled, M.; Lahti, L.; Lindholm, P.M.; Salmenkivi, K.; Bagwan, I.; Nicholson, A.G.; Knuutila, S. CDKN2A, NF2, and JUN are dysregulated among other genes by miRNAs in malignant mesothelioma -A miRNA microarray analysis. Gene. Chromosome. Canc. 2009, 48, 615–623. [Google Scholar] [CrossRef]
- Busacca, S.; Germano, S.; De Cecco, L.; Rinaldi, M.; Comoglio, F.; Favero, F.; Murer, B.; Mutti, L.; Pierotti, M.; Gaudino, G. MicroRNA Signature of Malignant Mesothelioma with Potential Diagnostic and Prognostic Implications. Am. J. Respir. Cell Mol. Biol. 2010, 42, 312–319. [Google Scholar] [CrossRef]
- Mitchell, P.S.; Parkin, R.K.; Kroh, E.M.; Fritz, B.R.; Wyman, S.K.; Pogosova-Agadjanyan, E.L.; Peterson, A.; Noteboom, J.; O'Briant, K.C.; Allen, A.; Lin, D.W.; Urban, N.; Drescher, C.W.; Knudsen, B.S.; Stirewalt, D.L.; Gentleman, R.; Vessella, R.L.; Nelson, P.S.; Martin, D.B.; Tewari, M. Circulating microRNAs as stable blood-based markers for cancer detection. Proc. Natl. Acad. Sci. USA 2008, 105, 10513–10518. [Google Scholar] [CrossRef]
- Wang, K.; Zhang, S.; Marzolf, B.; Troisch, P.; Brightman, A.; Hu, Z.; Hood, L.E.; Galas, D.J. Circulating microRNAs, potential biomarkers for drug-induced liver injury. Proc. Natl. Acad. Sci USA 2009, 106, 4402–4407. [Google Scholar]
- Crispi, S.; Calogero, R.A.; Santini, M.; Mellone, P.; Vincenzi, B.; Citro, G.; Vicidomini, G.; Fasano, S.; Meccariello, R.; Cobellis, G.; Menegozzo, S.; Pierantoni, R.; Facciolo, F.; Baldi, A.; Menegozzo, M. Global gene expression profiling of human pleural mesotheliomas: identification of matrix metalloproteinase 14 (MMP-14) as potential tumour target. PLoS One 2009, 4, e7016. [Google Scholar] [CrossRef]
- Røe, O.D.; Anderssen, E.; Sandeck, H.; Christensen, T.; Larsson, E.; Lundgren, S. Malignant pleural mesothelioma: genome-wide expression patterns reflecting general resistance mechanisms and a proposal of novel targets. Lung Cancer 2010, 67, 57–68. [Google Scholar]
- Gordon, G.J.; Rockwell, G.N.; Godfrey, P.A.; Jensen, R.V.; Glickman, J.N.; Yeap, B.Y.; Richards, W.G.; Sugarbaker, D.J.; Bueno, R. Validation of genomics-based prognostic tests in malignant pleural mesothelioma. Clin. Cancer Res. 2005, 11, 4406–4414. [Google Scholar] [CrossRef]
- Pass, H.I.; Liu, Z.; Wali, A.; Bueno, R.; Land, S.; Lott, D.; Siddiq, F.; Lonardo, F.; Carbone, M.; Draghici, S. Gene expression profiles predict survival and progression of pleural mesothelioma. Clin. Cancer Res. 2004, 10, 849–859. [Google Scholar] [CrossRef]
- Gordon, G.J.; Dong, L.; Yeap, B.Y.; Richards, W.G.; Glickman, J.N.; Edenfield, H.; Mani, M.; Colquitt, R.; Maulik, G.; Van Oss, B.; Sugarbaker, D.J.; Bueno, R. Four-gene expression ratio test for survival in patients undergoing surgery for mesothelioma. J. Natl. Cancer Inst. 2009, 101, 678–686. [Google Scholar] [CrossRef]
- Schouwink, H.; Korse, C.M.; Bonfrer, J.M.; Hart, A.A.; Baas, P. Prognostic value of the serum tumour markers Cyfra 21-1 and tissue polypeptide antigen in malignant mesothelioma. Lung Cancer 1999, 25, 25–32. [Google Scholar]
- Hedman, M.; Arnberg, H.; Wernlund, J.; Riska, H.; Brodin, O. Tissue polypeptide antigen (TPA), hyaluronan and CA 125 as serum markers in malignant mesothelioma. Anticancer Res. 2003, 23, 531–536. [Google Scholar]
- Thylén, A.; Hjerpe, A.; Martensson, G. Hyaluronan content in pleural fluid as a prognostic factor in patients with malignant pleural mesothelioma. Cancer 2001, 92, 1224–1230. [Google Scholar] [CrossRef]
- Filiberti, R.; Marroni, P.; Neri, M.; Ardizzoni, A.; Betta, P.G.; Cafferata, M.A.; Canessa, P.A.; Puntoni, R.; Ivaldi, G.P.; Paganizzi, M. Serum PDGF-AB in pleural mesothelioma. Tumour Biol. 2005, 26, 221–226. [Google Scholar] [CrossRef]
- Aoe, K.; Hiraki, A.; Tanaka, T.; Gemba, K.; Taguchi, K.; Murakami, T.; Sueoka, N.; Kamei, T.; Ueoka, H.; Sugi, K.; Yoshino, T.; Kishimoto, T. Expression of vascular endothelial growth factor in malignant mesothelioma. Anticancer Res. 2006, 26, 4833–4836. [Google Scholar]
- Strizzi, L.; Catalano, A.; Vianale, G.; Orecchia, S.; Casalini, A.; Tassi, G.; Puntoni, R.; Mutti, L.; Procopio, A. Vascular endothelial growth factor is an autocrine growth factor in human malignant mesothelioma. J. Pathol. 2001, 193, 468–475. [Google Scholar] [CrossRef]
- Yarden, Y. EGFR family and its ligand in human cancer. Signalling mechanisms and therapeutic opportunities. Eur. J. Cancer 2001, 37, S3–S8. [Google Scholar] [CrossRef]
- Dazzi, H.; Hasleton, P.S.; Thatcher, N.; Wilkes, S.; Swindell, R.; Chatterjee, A.K. Malignant pleural mesothelioma and epidermal growth factor receptor (EGF-R). Relationship of EGF-R with histology and survival using fixed paraffin embedded tissue and the F4, monoclonal antibody. Br. J. Cancer 1990, 61, 924–926. [Google Scholar] [CrossRef]
- Edwards, J.G.; Swinson, D.E.; Jones, J.L.; Waller, D.A.; O'Byrne, K.J. EGFR expression: associations with outcome and clinicopathological variables in malignant pleural mesothelioma. Lung Cancer 2006, 54, 399–407. [Google Scholar] [CrossRef]
- Pinton, G.; Brunelli, E.; Murer, B.; Puntoni, R.; Puntoni, M.; Fennell, D.A.; Gaudino, G.; Mutti, L.; Moro, L. Estrogen receptor–beta affects the prognosis of human malignant mesothelioma. Cancer Res. 2009, 69, 4598–4604. [Google Scholar] [CrossRef]
- Soini, Y.; Kinnula, V.; Kaarteenaho-Wiik, R.; Kurttila, E.; Linnainmaa, K.; Pääkkö, P. Apoptosis and expression of apoptosis regulating proteins bcl-2, mcl-1, bcl-X, and bax in malignant mesothelioma. Clin. Cancer Res. 1999, 5, 3508–3515. [Google Scholar]
- Kokturk, N.; Firat, P.; Akay, H.; Kadilar, C.; Ozturk, C.; Zorlu, F.; Gungen, Y.; Emri, S. Prognostic significance of Bax and Fas ligand in erionite and asbestos induced Turkish malignant pleural mesothelioma. Lung Cancer 2005, 50, 189–198. [Google Scholar] [CrossRef]
- Gordon, G.J.; Mani, M.; Mukhopadhyay, L.; Dong, L.; Edenfield, H.R.; Glickman, J.N.; Yeap, B.Y.; Sugarbaker, D.J.; Bueno, R. Expression patterns of inhibitor of apoptosis proteins in malignant pleural mesothelioma. J. Pathol. 2007, 211, 447–454. [Google Scholar] [CrossRef]
- Edwards, J.G.; McLaren, J.; Jones, J.L.; Waller, D.A.; O'Byrne, KJ. Matrix metalloproteinases 2 and 9 (gelatinases A and B) expression in malignant mesothelioma and benign pleura. Br. J. Cancer 2003, 88, 1553–1559. [Google Scholar] [CrossRef]
- Edwards, J.G.; Faux, S.P.; Plummer, S.M.; Abrams, K.R.; Walker, R.A.; Waller, D.A.; O'Byrne, K.J. Cyclooxygenase-2 expression is a novel prognostic factor in malignant mesothelioma. Clin. Cancer Res. 2002, 8, 1857–1862. [Google Scholar]
- O'Kane, S.L.; Cawkwell, L.; Campbell, A.; Lind, M.J. Cyclooxygenase-2 expression predicts survival in malignant pleural mesothelioma. Eur. J. Cancer 2005, 41, 1645–1648. [Google Scholar] [CrossRef]
- Zucali, P.A.; Giaccone, G. Biology and management of malignant pleural mesothelioma. Eur. J. Cancer 2006, 42, 2706–2714. [Google Scholar] [CrossRef]
- Jahan, T.; Gu, L.; Wang, X.; Kratzke, R.; Green, M.; Vokes, E.; Kindler, H. Vatalanib in patients with previously untreated advanced malignant mesothelioma (MM): Preliminary analysis of a phase II study by the Cancer and Leukemia Group B (CALGB 30107). Lung Cancer 2005, 49, S221. [Google Scholar]
- Baas, P.; Boogerd, W.; Dalesio, O.; Haringhuizen, A.; Custers, F.; van Zandwijk, N. Thalidomide in patients with malignant pleural mesothelioma. Lung Cancer 2005, 48, 291–296. [Google Scholar] [CrossRef]
- Kindler, H.L.; Vogelzang, N.J.; Chien, K. SU5416 in malignant mesothelioma: A University of Chicago phase II consortium study. J. Clin. Oncol. 2001, 2, 1359. [Google Scholar]
- Jänne, P.A.; Wang, X.F.; Krug, L.M.; Hodgson, L.; Vokes, E.E.; Kindler, H.L. Phase II trial of sorafenib (BAY 43–9006) in malignant mesothelioma: CALGB 30307. Lung Cancer 2006, 54, S51. [Google Scholar]
- Huang, S.M.; Harari, PM. Epidermal growth factor receptor inhibition in cancer therapy: biology, rationale and preliminary clinical results. Invest. New Drugs 1999, 17, 259–269. [Google Scholar] [CrossRef]
- Govindan, R.; Kratzke, R.A.; Herndon, J.E., II; Niehans, G.A.; Vollmer, R.; Watson, D.; Green, M.R.; Kindler, H.L. Cancer and Leukemia Group B (CALGB 30101). Gefitinib in patients with malignant mesothelioma: a phase II study by the Cancer and Leukemia Group B. Clin. Cancer Res 2005, 11, 2300–2304. [Google Scholar] [CrossRef]
- Garland, L.L.; Rankin, C.; Gandara, D.R.; Rivkin, S.E.; Scott, K.M.; Nagle, R.B.; Klein-Szanto, A.J.; Testa, J.R.; Altomare, D.A.; Borden, E.C. Phase II study of erlotinib in patients with malignant pleural mesothelioma: a Southwest Oncology Group Study. J. Clin. Oncol. 2007, 25, 2406–2413. [Google Scholar] [CrossRef]
- Kelly, W.K.; O'Connor, O.A.; Krug, L.M.; Chiao, J.H.; Heaney, M.; Curley, T.; MacGregore-Cortelli, B.; Tong, W.; Secrist, J.P.; Schwartz, L.; Richardson, S.; Chu, E.; Olgac, S.; Marks, P.A.; Scher, H.; Richon, V.M. Phase I study of an oral histone deacetylase inhibitor, suberoylanilide hydroxamic acid, in patients with advanced cancer. J. Clin. Oncol. 2005, 23, 3923–3931. [Google Scholar] [CrossRef]
- Park, D.J.; Lenz, H.J. The role of proteasome inhibitors in solid tumors. Ann. Med. 2004, 36, 296–303. [Google Scholar] [CrossRef]
- Zangemeister-Wittke, U.; Hopkins-Donaldson, S. Apoptosis regulation and drug resistance in malignant pleural mesothelioma. Lung Cancer 2005, 49, 105–108. [Google Scholar] [CrossRef]
- Gordon, G.J.; Mani, M.; Mukhopadhyay, L.; Dong, L.; Yeap, B.Y.; Sugarbaker, D.J.; Bueno, R. Inhibitor of apoptosis proteins are regulated by tumour necrosis factor-alpha in malignant pleural mesothelioma. J. Pathol. 2007, 211, 439–446. [Google Scholar] [CrossRef]
- Smythe, W.R.; Mohuiddin, I.; Ozveran, M.; Cao, X.X. Antisense therapy for malignant mesothelioma with oligonucleotides targeting the bcl-xl gene product. J. Thorac. Cardiovasc. Surg. 2002, 123, 1191–1198. [Google Scholar] [CrossRef]
- Altomare, D.A.; You, H.; Xiao, G.H.; Ramos-Nino, M.E.; Skele, K.L.; De Rienzo, A.; Jhanwar, S.C.; Mossman, B.T.; Kane, A.B.; Testa, J.R. Human and mouse mesotheliomas exhibit elevated AKT/PKB activity, which can be targeted pharmacologically to inhibit tumor cell growth. Oncogene 2005, 24, 6080–6089. [Google Scholar] [CrossRef]
- Hassan, R.; Remaley, A.T.; Sampson, M.L.; Zhang, J.; Cox, D.D.; Pingpank, J.; Alexander, R.; Willingham, M.; Pastan, I.; Onda, M. Detection and quantitation of serum mesothelin, a tumor marker for patients with mesothelioma and ovarian cancer. Clin. Cancer Res. 2006, 12, 447–453. [Google Scholar] [CrossRef]
- Grigoriu, B.D.; Chahine, B.; Vachani, A.; Gey, T.; Conti, M.; Sterman, D.H.; Marchandise, G.; Porte, H.; Albelda, S.M.; Scherpereel, A. Kinetics of soluble mesothelin in patients with malignant pleural mesothelioma during treatment. Am. J. Respir. Crit. Care Med. 2009, 179, 950–954. [Google Scholar] [CrossRef]
© 2010 by the authors; licensee Molecular Diversity Preservation International, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution license (http://creativecommons.org/licenses/by/3.0/).
Share and Cite
Tomasetti, M.; Santarelli, L. Biomarkers for Early Detection of Malignant Mesothelioma: Diagnostic and Therapeutic Application. Cancers 2010, 2, 523-548. https://doi.org/10.3390/cancers2020523
Tomasetti M, Santarelli L. Biomarkers for Early Detection of Malignant Mesothelioma: Diagnostic and Therapeutic Application. Cancers. 2010; 2(2):523-548. https://doi.org/10.3390/cancers2020523
Chicago/Turabian StyleTomasetti, Marco, and Lory Santarelli. 2010. "Biomarkers for Early Detection of Malignant Mesothelioma: Diagnostic and Therapeutic Application" Cancers 2, no. 2: 523-548. https://doi.org/10.3390/cancers2020523